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ABSTRACT 
 
Diabetic Sensory Neuropathy (DSN) presents with a constellation of sensory abnormalities, 
including numbness, tingling sensations, exacerbated responses to painful and non-painful 
stimuli, and a paradoxical loss of pain sensation. Despite the substantial burden that DSN 
afflicts on patients, the underlying mechanisms contributing to the pathogenesis of this disorder 
remains poorly understood. Particular interest has been concentrated on voltage-gated sodium 
(Nav) channels, especially their roles in painful forms of neuropathies in long-term diabetes. 
However, their possible contributions to the onset of neuropathy are still under investigation. 
  
This project aimed at elucidating the roles of Nav channels during the early stages of DSN in 
sensory neurons from the dorsal root ganglion (DRG). We used cultured DRG neurons, 
maintained in either control (5 mM glucose) or in high glucose media (25 mM) for up to 14 
days for patch-clamp electrophysiology. In addition, we used intact DRG tissues from 
streptozotocin (STZ)-induced diabetic mice, at one and three months after diabetes induction 
for the detection of Nav subunit expression. Our results indicate that DRG neurons maintained 
in high glucose show reduced action potential firing frequency and reduced inward currents. In 
addition, we observed a significant downregulation in the TTX-S Nav1.3, Nav1.6, and Nav1.7 
subunits in intact DRG tissues from one-month STZ-diabetic mice. The Navβ2 subunit, which 
has been shown to regulate the cell surface expression of TTX-S Nav channels, also shows 
statistically significant reductions in its expression levels. Interestingly, after three months of 
STZ-induced diabetes, there was a significant upregulation in the expression level of the TTX-
S Nav1.7 subunit. Taken together, our data reveal that changes causing reduction of expression 
and function of TTX-S Nav subunits take place at early stages in diabetes, while increased 
expression in Nav subunits occurs later in the disease. Therefore, our data suggest a potential 
role for Nav subunits in the development of the various sensory symptoms in DSN. 
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CHAPTER 1 
INTRODUCTION 
1.1. Diabetic Peripheral Neuropathy 
Diabetes mellitus (DM) is a chronic metabolic disease characterized by deficiency in insulin 
production (Type 1) or resistance to insulin action (Type 2) (Kobayashi and Zochodne, 2018). 
Including both types 1 and 2, it was estimated that DM affected 415 million people worldwide in 
2015, and its prevalence is predicted to rise to 642 million by 2040 (Ogurtsova et al., 2017). DM 
is linked to various forms of cellular and molecular disturbances in glucose and lipid metabolism, 
which lead to the activation of a host of complex biochemical pathways, making treatment highly 
challenging (Brownlee, 2001; Tomlinson and Gardiner, 2008). The hallmark feature of DM is 
hyperglycemia, or elevated levels of blood glucose, which is considered central to the 
pathophysiology of the disease (Tomlinson and Gardiner, 2008). Hyperglycemia leads to the 
development of a variety of complications, the most common being diabetic peripheral 
neuropathy (DPN) (Kobayashi and Zochodne, 2018). DPN affects approximately 50% of diabetic 
patients, depending on age, duration of diabetes and glycemic control (Said, 2007; Cheing, 2010; 
Callaghan et al., 2012). Moreover, up to 20% of diabetic patients can also experience the painful 
form of DPN (Callaghan et al., 2012). Therefore, as the prevalence of diabetic patients increases, 
the population of patients afflicted by DPN also increases. 
 
Traditionally, DPN has been considered as the result of peripheral nerve damage after long-
standing diabetes (Tesfaye et al., 2010). However, studies reporting the occurrence of DPN in 
prediabetic patients (Suo et al., 2016; Feldman et al., 2017; Wilson, 2017) and children with Type 
1 DM (Louraki et al., 2012) are emerging. Moreover, it has been shown that patients with 
impaired glucose tolerance (but without overt diabetes) show early signs of neuropathy in skin 
biopsies, such as nerve fibre loss (Smith et al., 2001; Sumner et al., 2003). Ultimately, there is a 
need for a better understanding of the early mechanisms that initiate the pathogenesis of DPN 
before irreversible nerve damage ensues. DPN can affect all components of the peripheral 
nervous system, including sensory, motor and autonomic; however, DPN affecting sensory 
nerves is considered the most debilitating form (Tesfaye et al., 2010; Pop-Busui et al., 2017). 
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1.1.1. Diabetic Sensory Neuropathy (DSN) 
Diabetic Sensory Neuropathy (DSN) is a subtype of DPN that affects the sensory nerves leading 
to sensory abnormalities. Forms of DSN can present with a wide spectrum of clinical symptoms 
from tingling, numbness, weakness, and sensory loss, to exacerbated pain perception (Callaghan 
et al., 2012; Kobayashi and Zochodne, 2018). Patients suffering from DSN can display one or 
more types of stimulus-evoked pain such as exacerbated responses to noxious (hyperalgesia) or 
innocuous (allodynia) sensory stimuli, and pain is often worse at night for patients (Hong et al., 
2004; Tesfaye et al., 2010). The most common presentation for DSN is distal symmetrical 
polyneuropathy, in which sensory abnormalities most commonly manifest in a symmetrical 
“stocking-and-glove” distribution. Sensory abnormalities typically are experienced in the distal 
extremities (e.g., hands and feet) and progress proximally towards the torso over the course of 
diabetes (Callaghan et al., 2012). Consequently, diabetic patients are at a higher risk for 
developing foot ulcers, which can eventually contribute to lower limb amputations (Callaghan et 
al., 2012; Kobayashi and Zochodne, 2018). Ultimately, pathological damage to the peripheral 
nerves in DSN can be significantly debilitating, thereby resulting in considerable reduction in 
patient quality of life. Unfortunately, despite a strong relationship between blood glucose levels 
and neuropathy (The Diabetes Control and Complications Trial Research Group, 1993; Dyck et 
al., 1999), the underlying mechanisms contributing to the pathology of DSN are yet to be 
elucidated. Furthermore, while strict glycemic control and pain management are useful in DSN 
treatment, they are insufficient in arresting the progression of DSN. In addition, tight glycemic 
control has been shown to be more effective in preventing neuropathies in Type 1 DM, compared 
to Type 2 DM, potentially because of the differences in their underlying mechanisms (Vinik et 
al., 2000; Feldman et al., 2017). Therefore, unfortunately, there is no therapeutic strategy that has 
been successful in halting or reversing the progression of DSN (Boucek, 2006; Callaghan et al., 
2012; Kobayashi and Zochodne, 2018). 
  
1.1.2. Paradoxical Loss of Pain Perception and Pain Abnormalities in DSN 
As mentioned above, DSN presents with a variety of sensory abnormalities, and the presence of 
both positive and negative symptoms in DSN is common. Patients can experience pain sensitivity 
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and paradoxical numbness at the same time (Callaghan et al., 2012). One of the biggest 
consequences of sensory loss in diabetes is “diabetic foot”. The diabetic foot results from lack of 
sensation making the feet susceptible to the recurring formations of unnoticed wounds or ulcers 
on a background of impaired wound healing. If left untreated, infections and gangrene can occur, 
leading to lower limb amputations (Jeffcoate and Harding, 2003). To prevent irreversible lower 
limb amputations, DSN patients are always advised to regularly check their feet for wounds and 
ulcers, and wear comfortable footwear (Pop-Bususi et al., 2017). 
 
 Along with the paradoxical loss of pain perception, patients also report painful sensations 
described as stabbing, electric or burning sensations (Kaur S. et al., 2011). Later on, as a result of 
long-standing diabetes, these incapacitating pain symptoms disappear, which unfortunately is a 
manifestation of the irreversible structural loss of sensory axons in the lower extremities 
(Boucek, 2006). During the onset of DSN, however, it is still under investigation if there are any 
early molecular and/or biochemical disturbances that contribute to the typical heterogeneous 
constellation of symptoms. The effects of hyperglycemia on neurons have been the focus of 
studies aiming at elucidating the pathogenesis of DSN. 
  
1.1.3. Effect of Hyperglycemia on Neurons 
Neurons are particularly vulnerable to the damages resulting from high glucose levels because 
neuronal glucose uptake is mostly dependent on the extracellular concentration of glucose (Patel 
et al., 1994; Tomlinson and Gardiner, 2008). Neurons are considered insulin-insensitive 
regarding glucose uptake, since the effects of insulin are markedly weaker in neurons than in 
other tissues. Glucose transporters 1 and 3 (GLUT1 and GLUT3) are uniporter transport proteins 
that mediate the facilitated transport of glucose across the plasma membrane of neurons, 
including those from the DRG (Rigon et al., 2013). Insulin, which has no effects on GLUT1 
(Simpson et al., 2008), can indirectly regulate neuronal glucose uptake by promoting 
translocation of GLUT3 to a vesicles pool available to fuse with the plasma membrane. Fusion of 
GLUT3 to the plasma membrane is ultimately triggered by neuronal depolarization during 
periods of activity requiring the uptake of glucose (Uemura and Greenlee, 2006). Under diabetic 
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conditions, persistent hyperglycemia can result in up to a fourfold increase in glucose levels in 
neurons, making them more vulnerable to hyperglycemia-induced damage (Tomlinson and 
Gardiner, 2008). The hyperglycemia-induced neuronal insult is linked to a number of 
biochemical changes that ultimately lead to nerve damage. Proposed etiologies of DSN include 
increased polyol pathway flux leading to osmotic stress, increased hexosamine pathway flux and 
protein kinase C (PKC) activation resulting in altered gene expression and protein function, 
formation of advanced glycation end-products (AGEs), oxidative stress and inflammatory injury 
(for review, see: Brownlee, 2001; Tomlinson & Gardiner, 2008). AGEs are formed by the non-
enzymatic glycation of proteins, nucleotides and lipids (Thornalley, 2002), which can lead to 
cross-linking of intra- and extracellular proteins, protein aggregation, and alterations in protein 
function (Vincent et al., 2007). Moreover, AGEs can bind to their receptor called RAGE 
(receptor for AGE), activating downstream signalling cascades leading to oxidative stress and 
inflammatory injury (Brownlee, 2001). In fact, RAGE signalling has been implicated in 
mechanisms of sensitization in sensory neurons under high glucose conditions (Lam et al., 2018). 
These complex pathological pathways contribute to the functional outcomes of DSN, such as 
reduced nerve conduction velocities, pain and impaired axonal regenerative capacity (Tomlinson 
and Gardiner, 2008). 
 
1.2 The Sensory Nervous System and Pain Perception 
The main role of primary sensory neurons is to convey sensory information from their innervated 
receptive fields to the central nervous system (CNS) for sensory integration. Sensory (afferent) 
nerves, along with motor (efferent) nerves, comprise the somatic nervous system, which is a 
branch of the peripheral nervous system. Humans have 31 pairs of spinal nerves categorized into 
regional segments as follows: 8 cervical, 12 thoracic, 5 lumbar, 5 sacral and 1 coccygeal 
(Krames, 2014). In the spinal cord, the dorsal horn receives sensory innervation from the dorsal 
root ganglion (DRG) via the neural foramina (Sapunar et al., 2012). The DRG contain cell bodies 
of sensory neurons that transduce sensory information from their peripheral terminals and 
transmit these signals to the dorsal horn of the spinal cord and eventually to the appropriate brain 
regions (Krames, 2014). As Figure 1.1 illustrates, DRG neurons are pseudo-unipolar cells with a 
single process that bifurcates into a peripheral branch, which innervates target tissues and organs 
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(e.g. skin), and a central branch, which synapses onto second order sensory neurons in the dorsal 
horn of the spinal cord within laminae I and II in the case of C-fibers, and within laminae I and V 
for Aδ-fibres (Kandel et al., 2013). Pain, together with itch, temperature, and visceral 
information, is conveyed to the spinal cord by small-diameter myelinated and unmyelinated 
fibers. This information is conveyed across the midline within the spinal cord and transmitted to 
the brain stem and the thalamus in the contralateral anterolateral column, which then sends 
information to the somatosensory cortex (see Fig. 1.1) (Kandel et al., 2013). DRG neurons can 
span up to 1.5 meters in length, and are among the largest cells in the body (Hogan, 2010; 
Krames, 2014). Moreover, the DRGs are outside the blood-nerve barrier, and thus they are 
exposed to the circulating substances in the blood, including high levels of glucose in the case of 
DM (Sapunar et al., 2012). 
 
Pain sensation is mediated by the small unmyelinated C-fibre neurons and the small to medium 
thinly-myelinated Aδ fibres from the DRGs; while Aβ fibres carry non-painful tactile sensory 
stimuli (Lai et al., 2004). Both small and large sensory fibres experience irreversible damage in 
DSN (Hong and Wiley, 2006; Jin and Park, 2017). In the late stages of diabetes, damage in these 
sensory neurons results in a “dying back” process of neurodegeneration, where distal axon 
terminals are more affected than axons in the proximal sites (Kobayashi and Zochodne, 2018). 
Yagihashi et al. (2011) proposed that DRG distal terminals are more vulnerable to the damages 
inflicted by diabetes because peripheral processes are of extended lengths, and thus nutrient and 
trophic support requires long transports from the cell body to the distal peripheral terminals. Over 
time, the largest and longest sensory processes innervating the hip, leg and feet display the most 
damage in DSN (Said, 2007; Kaur S. et al., 2011). Consequently, the present study included 
DRG neurons from the lumbar 1-5 regions of the spinal cord, which contain long sensory 
processes innervating the lower extremities. 
 
DRG neurons express the transient receptor potential for vanilloid 1 (TRPV1) nonselective cation 
channel (Szallasi et al., 2007). This receptor is activated by a variety of ligands including 
capsaicin, which is the active ingredient found in chilli peppers (Szallasi et al., 2007).  Activation 
of the TRPV1 channel causes a depolarization at the peripheral terminal, which if strong enough 
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can activate voltage-gated sodium (Nav) channels to fire an action potential (AP). The AP sends 
information from the peripheral terminal to the relay station in the spinal cord, from which the 
information is sent to the brain to be integrated as sensory perception (Boron and Boulpaep, 
2017). Due to their central role in initiating AP firing, Nav channels have been implicated in the 
pathogenesis of DSN (Hirade et al., 1999; Craner et al., 2002; Hong et al., 2004; Hong and 
Wiley, 2006; Yang et al., 2016). Moreover, a strong correlation between Nav subunit expression 
and pain conditions has been shown in diabetic animal models and humans (Waxman et al., 
1999; Benarroch, 2007; Tibbs et al., 2016). However, these studies mainly focused on the long-
term effects of hyperglycemia, and the exact roles of Nav channels during the early stages of 
DSN are still under investigation. 
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Figure	  1.1.	  Diagram	  depicting	  a	  nociceptive	  pathway	  between	  the	  periphery	  and	  the	  spinal	  cord.	  Nociceptive	  fibers	  from	  pseudounipolar	  DRG	  neurons	  innervating	  the	  skin	  and	  viscera	  converge	  on	  projection	  neurons	  in	  the	  dorsal	  horn	  of	  the	  spinal	  cord.	  Sensory	  information	  is	  then	   carried	   by	   fibres	   of	   the	   anterolateral	   column	   pathway	   to	   the	   brain	   stem	   and	   the	  thalamus,	  and	  finally	  to	  the	  somatosensory	  cortex.	  	  (Modified	  from	  Kandel	  et	  al.,	  2013) 
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1.3. Voltage-Gated Sodium (Nav) Channels and AP Firing         
In the peripheral terminals of DRG neurons, transducer receptors convert mechanical or chemical 
stimuli into an electrical signal called receptor potential. Receptor potentials are graded responses 
that if it causes a depolarization (membrane potential going in the positive direction) beyond a 
certain threshold voltage, an action potential response is initiated. An action potential (AP) is a 
regenerative all-or-none response of electrically excitable cells such as neurons (Boron and 
Boulpaep, 2017).  It consists of three phases — a depolarizing phase, a repolarizing phase and a 
hyperpolarizing phase. The first phase of an AP is the depolarizing phase, wherein the membrane 
potential (Vm) of the cell becomes more positive. In DRG neurons, the Vm of a DRG neuron 
changes from a negative (usually around -60 mV) to a positive value until reaching the peak of 
the AP. The second phase involves the repolarizing of the membrane potential or returning to its 
resting value. The hyperpolarization phase occurs in APs of most excitable cells, where the Vm 
falls below the resting membrane potential (Vrest) before going back to Vrest (Boron and 
Boulpaep, 2017). Seminal work by Hodgkin and Huxley (1952) showed that APs occur due to 
the influx of Na+ ions and efflux of K+ ions (Hodgkin and Huxley, 1952) through voltage-gated 
channels (Boron and Boulpaep, 2017).  
 
Voltage-gated sodium (Nav) channels are responsible for the depolarizing phase of APs. Nav 
channels are expressed throughout the nervous system, and they play critical roles in action 
potential generation and transmitting sensory information to the CNS (Catterall, 1992; Waxman 
et al., 1999). As Figure 1.2 shows, Nav channels are composed of a large α-subunit, which 
associates with one or two auxiliary β-subunits (Lopez-Santiago et al., 2006; Benarroch, 2007). 
The α-subunit forms the ion-selective and voltage-sensitive pore of the channel (Lauria et al., 
2014), while the β-subunit modulates Nav channel gating and membrane localization to distinct 
neuronal domains (Lopez-Santiago et al., 2006). The α-subunit is comprised of four homologous 
domains (domains I-IV), and each domain is made up of six α-helices called segments 1-6 (S1-
S6) (Wang et al., 2011). The pore of the channel is composed of S5, S6 and a pore-loop (P-loop) 
that connects the two segments (De Lera Ruiz and Kraus, 2015). The voltage-sensing domain is 
formed by S1-S4, which regulates channel gating in response to membrane depolarization (De 
Lera Ruiz and Kraus, 2015). It has been proposed that membrane depolarization causes the S4 
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domain, which contains repetition of positively charged residues, to spiral outward towards the 
extracellular space, resulting in a conformational change that opens the pore of the channel 
(Wang et al., 2011). The latter results in activation of the channel, allowing sodium influx and 
further membrane depolarization to occur (Catterall, 1992). A key element of the Nav channel is 
the inactivation gate, which is formed by the intracellular loop between domains III and IV and 
acts as a hinged lid that plugs the pore of the channel in response to membrane depolarization (De 
Lera Ruiz and Kraus, 2015). Therefore, Nav channels exist in three functional states: closed, 
activated and inactivated (Figure 1.3) (Bagal et al., 2015). Nav channel activation causes 
depolarization, which in turn activates a larger population of Nav channels by a positive feedback 
mechanism. The latter is responsible for the rapidly rising phase of the AP. Following activation 
and while the cell is still depolarized, Nav channels enter an inactivated state, in which any 
further influx of Na+ is prevented. The inactivation state is finally removed when Vm is restored 
(or by afterhyperpolarization), allowing the channels to return to the closed state and be ready for 
a new activation phase (Namadurai et al., 2015).  
 
The α-subunit of Nav channels associates with one or two auxiliary β-subunits. β-subunits belong 
to the immunoglobulin superfamily of cell-adhesion molecules (Namadurai et al., 2015). To date, 
there are five β-subunits — β1, β1B, β2, β3 and β4. SCN1B-SCN4B encodes the four β-subunits 
and alternative splicing of the SCN1B gene results in the formation of the β1B subunit 
(Brackenbury and Isom, 2011; Namadurai et al., 2015). β1 and β3 noncovalently bind to the α-
subunit, while β2 and β4 covalently attach to the α-subunit via disulfide bonds (Namadurai et al., 
2015). β-subunits modulate gating, voltage-dependence and kinetics of Nav channels 
(Brackenbury and Isom, 2011). Among the different β subunits, Navβ2 have garnered much 
attention in pain research because SCN2B null mice exhibit altered pain responses (Pertin, 2005; 
Lopez-Santiago et al., 2006). During the biosynthesis of the Nav channels, Navβ2 associates with 
the α-subunit to enable plasma membrane insertion of the channel and thereby increases Nav 
current (Schmidt and Catterall, 1986). It has been proposed that the role of Navβ2 in vivo is to 
regulate tetrodotoxin-sensitive (TTX-S) Nav channels (Lopez-Santiago et al., 2006; Brackenbury 
and Isom, 2011). Lopez-Santiago and colleagues (2006) demonstrated that DRG neurons from 
β2—/— mice have significant reductions in TTX-S Nav currents compared to those from β2+/+ 
mice and the observed decrease in TTX-S currents was supported by reductions in TTX-S Nav1.7 
10	  	  
transcripts and protein levels.  Furthermore, β2—/— mice display increased sensitivity to noxious 
thermal stimuli (Lopez-Santiago et al., 2006), suggesting that  Navβ2 may play key roles in the 
development of pain in neuropathic states. 
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Figure	   1.2.	  The	  primary	   structure	  of	  Nav	   channels	   is	   composed	   of	   a	   large	  α-­‐subunit	   and	  one	   or	   two	   auxiliary	   β-­‐subunits.	   The	   α-­‐subunit	   is	   made	   up	   of	   four	   domains,	   and	   each	  domain	   is	   formed	  by	  six	  α-­‐helical	   segments.	  The	  α-­‐subunit	   folds	   to	   form	  the	   ion-­‐selective	  and	  voltage-­‐sensitive	  pore	  of	  the	  Nav	  channel.	  On	  the	  other	  hand,	  the	  β-­‐subunit	  modulates	  channels	  gating	  and	  localization.	  	  (Reproduced	  with	  permission	  from	  	  Benarroch,	  2007)	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Figure	  1.3.	  Nav	  channels	  cycle	  through	  three	  different	  states:	  closed,	  open	  and	  inactivated.	  A	   depolarization	   can	   activate	  Nav	   channels	   from	   the	   resting	   (closed)	   state	   into	   the	   open	  conformation	  to	  allow	  the	  influx	  of	  Na+	  ions.	  During	  depolarization,	  Nav	  channels	  enter	  an	  inactivated	  state	  where	  the	  inactivation	  gate	  acts	  as	  a	  hinged	  lid	  that	  plugs	  the	  pore	  of	  the	  channel.	  Then,	   a	   hyperpolarized	  membrane	   potential	  will	   return	   the	  Nav	  channel	   into	   its	  resting	   closed	   conformation,	   and	   the	   cycle	   will	   repeat	   for	   the	   next	   voltage	   stimulus.	  
(Modified from Bagal et al., 2015) 
Inactivation 
gate 
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1.3.1 Pharmacological Characterization of Nav Isoforms  
There are nine Nav1 subtypes, Nav1.1 to Nav1.9, that have well-defined roles in neuronal 
physiology, and a novel family of Nav2 channels, whose function is still under investigation (De 
Lera Ruiz and Kraus, 2015). The different mammalian Nav isoforms display different kinetics 
and voltage dependencies (Benarroch, 2007; Waxman, 2012) and as a group, they are more than 
50% homologous in their amino acid sequences (Goldin et al., 2000). The genes that encode 
different Nav isoforms are SCN1A (Nav1.1), SCN2A (Nav1.2), SCN3A (Nav1.3), SCN4A 
(Nav1.4), SCN5A (Nav1.5), SCN8A (Nav1.6), SCN9A (Nav1.7), SCN10A (Nav1.8) and 
SCN11A (Nav1.9) (De Lera Ruiz and Kraus, 2015). Nav isoforms can be pharmacologically 
classified according to their sensitivity to tetrodotoxin (TTX), which is a toxin isolated from 
animals such as the puffer fish. TTX blocks some Nav channels by binding to a neurotoxin 
receptor site on its outer pore (Chong and Ruben, 2008). Nav1.1, Nav1.2, Nav1.3, Nav1.4, 
Nav1.6 and Nav1.7 can be blocked by nanomolar concentrations of TTX, and thus are considered 
TTX-sensitive (TTX-S). On the other hand, Nav1.5, Nav1.8 and Nav1.9 are inhibited only by 
micromolar concentrations of TTX, and hence are viewed as TTX-resistant (TTX-R) (De Lera 
Ruiz and Kraus, 2015). In DRG neurons, TTX-S currents are mediated by Nav1.1, 1.3, 1.6 and 
1.7, while TTX-R currents are carried by Nav1.8 and Nav1.9 (Benarroch, 2007). Most small 
DRG neurons have fast TTX-S Nav currents and a majority of them also co-express slow, TTX-R 
Nav currents (Parnham et al., 2005). 
  
In addition, Nav channels are sensitive to local anaesthetics, such as lidocaine. Local anaesthetics 
work by blocking Nav channels in their inactivated state (De Lera Ruiz and Kraus, 2015). It is 
generally considered that lidocaine binds to the S6 segment of domain IV in the pore of the 
channel (Ragsdale et al., 1994). The mechanism of action of lidocaine makes it useful clinically 
as an antiarrhythmic and anaesthetic drug (De Lera Ruiz and Kraus, 2015). Moreover, lidocaine 
has been proposed as a treatment for neuropathic pain (Bach et al., 1990; Mao and Chen, 2000; 
Derry et al., 2014; Casale et al., 2017). Routes of administration include topical, oral and 
intravenous.  
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1.3.2. Nav Channels in Pain Abnormalities 
Nociceptors express various Nav isoforms, such as Nav1.7, Nav1.8 and Nav1.9 (Rush et al., 
2007). These isoforms have been implicated in the pathogenesis of multiple forms of neuropathic 
pain in humans and display distinct electrophysiological properties (Tibbs et al., 2016). First, 
Nav1.7 activates in response to small depolarizations, and serves to boost subthreshold stimuli 
(depolarizations that are below the voltage threshold to trigger an action potential response) to 
enable AP firing (Waxman, 2012). Nav1.7 is found in DRG and sympathetic neurons (Benarroch, 
2007) and mutations in SCN9A gene have been linked to hereditary pain disorders such as 
primary erythromelalgia, paroxysmal extreme pain disorder and small fibre neuralgia (De Lera 
Ruiz and Kraus, 2015; Tibbs et al., 2016). Moreover, loss-of-function mutations in the SCN9A 
gene has been linked to congenital insensitivity to pain, a condition in which patients do not feel 
pain during situations such as childbirth, tooth extraction and broken bones (De Lera Ruiz and 
Kraus, 2015). Therefore, Nav1.7 plays key roles in the development of pain abnormalities and 
potentially during the onset of DSN. 
 
Next, Nav1.8 carries majority of the inward current during the upstroke of the action potential 
and is specifically expressed in DRG neurons (Benarroch, 2007). Renganathan and colleagues 
(2001) demonstrated that Nav1.8+/+ C-type DRG neurons were able to produce APs, while 
Nav1.8—/— DRG neurons only fire small graded potentials (Renganathan et al., 2017). Moreover, 
mutations in the SCN10A gene has been found in patients with painful small-fibre neuropathy 
(Faber et al., 2012). Nav1.7 and Nav1.8 have been proposed to work together during repetitive 
firing in DRG neurons (Lauria et al., 2014; De Lera Ruiz and Kraus, 2015). A study by Rush and 
colleagues (2006) demonstrated that one of the mutations (L858H) in the SCN9A gene identified 
in erythromelalgia has been shown to result in opposing phenotypes attributed to the presence or 
absence of the Nav1.8 channel. They showed that the L858H mutation in the SCN9A gene 
encoding for Nav1.7 results in a more depolarized Vrest in DRG neurons and sympathetic neurons 
from the superior cervical ganglion (SCG). However, this mutation resulted in hyperexcitability 
in DRG neurons and hypoexcitability in SCG neurons. These opposing effects have been 
associated with the presence or absence of the Nav1.8 channel in these cell types. DRG neurons 
have Nav1.8 and can sustain repetitive firing due to the depolarizations caused by Nav1.7, while 
SCG neurons lack the Nav1.8 channel and therefore the depolarizations caused by Nav1.7 
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inactivates other Nav channels (Nav1.3 and Nav1.6) ultimately leading to reduced excitability. 
(Rush et al., 2006; Benarroch, 2007). Moreover, diabetic patients have high levels of the reactive 
diacarbonyl methylglyoxal, which has been shown to induce post-translational modifications on 
Nav1.8 leading to increased excitability of nociceptive neurons and hyperalgesia (Bierhaus et al., 
2012). Given its selective expression in DRG neurons and involvement in pain abnormalities, 
dysregulations in Nav1.8 may be involved in the development of symptoms in early DSN. 
 
Nav1.9 produces a persistent current activated close to the resting membrane potential (Waxman, 
2012). Mutations in the SCN11A gene has been linked to inflammation-induced hyperalgesia 
(Priest et al., 2005) and hyperexcitabilty of DRG neurons in familial episodic pain (Zhang et al., 
2013).  Lastly, Nav1.3 has garnered much attention in the field of neuropathic pain research. 
Nav1.3 displays an increase in expression levels following peripheral nerve injury and has been 
proposed to contribute to DRG neuron hyperexcitability (Waxman, 2012). Injured DRG neurons 
have been reported to exhibit an increase in TTX-S Nav currents and a reduction in TTX-R Nav 
currents and these changes have been attributed to an increase in expression levels of the TTX-S 
Nav1.3 and a simultaneous downregulation of the TTX-R Nav1.8 and Nav1.9 (Lai et al., 2004). 
Ultimately, Nav channels have been linked to pain abnormalities and may therefore mediate the 
positive and negative symptoms that occur in DSN. 
 
1.4. Rationale and Hypothesis 
A study by Lam et al. (2018) further supports increased sensory neuron excitability in DM even 
during short-term states. They reported that cultured DRG neurons maintained in high glucose for 
up to a week showed increased oxidative stress and a potentiation of capsaicin-evoked currents. 
Subsequent unpublished observations surprisingly revealed, however, that these sensory neurons 
are less excitable and fire fewer APs upon electrical stimulation. The latter contradicts the general 
consensus that DRG neurons in DM are hyperexcitable causing increased pain perception and 
suggests that hyperglycemia may modulate excitability differently over the course of the disease. 
Therefore, to better understand the molecular mechanisms underlying these contradictory 
findings, we hypothesized that short-term (10-14 days) exposure to high glucose affects the 
function of voltage-gated Na+ (Nav) channels, which in turn affect the neuron’s ability to 
generate APs.  
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The ultimate goal of this project was to elucidate the short-term effects of diabetes on the 
expression and function of Nav channels in DRG neurons. We studied Nav channel function in 
DRG neurons after exposure to a high glucose media. Next, to determine whether the changes 
conferred by glucose on Nav channels in vitro occurs during the very early stages of diabetes, we 
investigated Nav expression levels in intact DRG tissue from our diabetic mouse model. Our 
findings revealed that hyperglycemia modulates Nav channel expression and function in DRG 
neurons and that this modulation changes through the course of the disease. We hope this project 
will shed better light on the pathogenesis of DSN, and will aid in the development of therapeutics 
that could prevent the onslaught of irreversible DSN progression. 
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CHAPTER 2 
MATERIALS AND METHODS 
 
2.1 Primary Lumbar DRG Cultures. Primary DRG cultures were prepared from lumbar 1-5 
[L1-L5] DRG neurons from C57BL/6 mouse pups between postnatal days 0-4 [P0-P4]. Briefly, 
DRGs were harvested under sterile conditions similar to the protocol for superior cervical 
ganglion neurons (Campanucci et al., 2008). The DRG neurons were utilized because they 
contain long processes, which display the most damage in DSN (Said, 2007). The removed 
ganglia were then dissociated at 37°C in Hanks’ balanced salt solution (HBSS) containing trypsin 
(1 mg/mL; Worthington, Freehold, NJ) and buffered with HEPES (N-2-hydroxyethylpiperazine-
N'-2-ethanesulfonic acid) for 45-60 minutes. Afterwards, the ganglia were triturated 50-100 times 
using fire-polished pipettes until dissociated. The resulting cell suspension was washed twice 
using serum-containing media to inactivate trypsin, then plated on laminin-coated glass bottom 
Petri dishes (Corning 35 mm) made in-house. The DRG neurons were maintained in a growth 
media made from Leibovitz’s L-15 medium supplemented with vitamins, cofactors, penicillin-
streptomycin, 5 mM glucose, 5% rat serum, and NGF (nerve growth factor, 10 ng/mL). The 
primary DRG cultures were kept at 37°C in a 95% air-5% CO2 atmosphere, and fed every 4-5 
days. To eliminate non-neuronal cells, cultures were treated with cytosine arabinoside (10 µM; 
Sigma, St. Louis, MO) containing media from days 2 to 4 after culturing. Cultures were 
maintained in either a control (5 mM; CTL) or high glucose (25 mM; HG) media for an 
additional 10-14 days before any whole-cell patch clamp experiments were performed. 
  
2.2 Animals. One-month-old male C57BL/6 mice were intraperitoneally injected with 
streptozotocin (STZ; 50 mg/kg) or with citrate buffer (control; CTL; pH=4.5) for 3 consecutive 
days. STZ is an antibiotic that destroys the insulin-producing β cells of the pancreas (Deeds et al., 
2011). STZ is taken up by β cells via the glucose transporter 2 (GLUT2), and causes DNA 
alkylation leading to cell death (Gleichmann and Wang, 1998; Szkudelski, 2001; Deeds et al., 
2011). After one or three month(s), intact L1-5 DRG tissues were collected from control and 
diabetic animals. Diabetes was defined as a final blood glucose level of 15 mM or greater. Initial 
measurements of body weight and blood glucose were taken at day 1 of STZ injections, while 
final measurements were taken on the day of euthanasia and sample collection. Control animals 
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with blood glucose levels above 10.5 mM during sample collection were considered prediabetic 
and were excluded from this study (Campanucci et al., 2010). Animals were provided access to 
normal rodent chow ad libitum. 
 
2.3 Whole-Cell Patch Clamp Electrophysiology. Primary DRG cultures maintained in either 
control (5 mM) or high glucose (25 mM) conditions were utilized in whole-cell patch-clamp 
electrophysiological experiments. Patch pipettes were made from borosilicate glass (World 
Precision Instruments, Sarasota, FL, USA) using a vertical puller (PC 10; Narishige Scientific 
Instrument Lab., Tokyo, Japan), and had a resistance of 3–8 MΩ when filled with intracellular 
recording solution. Recording electrodes were filled with the following intracellular solution (in 
mM): 60 KC2H3O2, 70 KF, 5 NaCl, 1 MgCl2, 1 CaCl2, 10 HEPES (N-2-hydroxyethylpiperazine-
N'-2-ethanesulfonic acid), 10 EGTA (ethylene glycol-bis(2-aminoethylether)-N,N,N’,N’-
tetraacetic acid) and 2 Mg-ATP (adenosine 5'-triphosphate magnesium salt), and pH was adjusted 
to  7.2 with KOH (all from Sigma–Aldrich). Cultured neurons were perfused continuously at 2 
mL/min with extracellular fluid (ECF) consisting of (in mM): 140 NaCl, 5.4 KCl, 0.33 NaH2PO4, 
0.44 KH2PO4, 2.8 CaCl2, 1 MgCl2, 10 HEPES, 5.0 glucose (all from Sigma-Aldrich); pH was 
adjusted to 7.4 with NaOH. Whole-cell currents or membrane potentials were recorded at room 
temperature with the aid of an Axopatch 200B amplifier (Molecular Devices, Palo Alto, CA, 
USA) equipped with a 1 GΩ headstage feedback resistor and a Digidata 1440A (Molecular 
Devices) and stored on a personal computer. Voltage- and current-clamp protocols, data 
acquisition, and analysis were performed using pCLAMP 10 software (Molecular Devices) and 
OriginPro 9.0 (OriginLab Corporation, Northampton, MA, USA). Patched DRG neurons were 
allowed to stabilize for 5 minutes before data collection. For voltage-clamp recordings, a 
hyperpolarizing prepulse of -120 mV was applied from a holding potential of -60 mV. Then, a 
step protocol from -80 mV to +30 mV at 10mV increments was applied to generate inward 
currents.  For current-clamp recordings, action potentials (AP) were generated by the injection of 
depolarizing current steps (100 pA intervals for 500 ms). In both configurations, additional 
perfusions with added 1 µM tetrodotoxin (TTX; Alomone Labs), and 1 µM TTX + 100 µM 
lidocaine (Sigma-Aldrich) were used to better isolate sodium currents. 
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2.4 Whole-Cell Currents Analysis. The TTX-sensitive (TTX-S) component of the whole-cell 
inward currents was isolated by subtracting recordings obtained with TTX from those without 
(control); while TTX-resistant (TTX-R) currents were isolated by subtracting recordings with 
TTX + lidocaine from those done with TTX alone. Conductance values were obtained by the 
following formula: 𝐺!" =    !!"!!!  !!"  …………..………………………..(2.1) 
 
Where GNa is the conductance for sodium ions (Na+), INa is the peak current at a specific test 
pulse, Vm is the voltage step, and ENa is the reversal potential for Na+. ENa was calculated to be    
+84.3 mV in the experiment setup using the Nernst equation. GNa was normalized to maximum 
conductance (Gmax). Steady-state activation curves were acquired by fitting normalized 
conductance (GNa/Gmax) values in the Boltzmann equation: 
 𝑦 = !!!!! ∗!!"#!!!(!!!!!"#)/!" …………………………………(2.2) 
 
Where, ENa is the reversal potential for Na+, Gmax is the maximal conductance, and Vhalf is the 
membrane potential at half-maximal activation. 
 
2.5 Western Blotting. DRG tissue samples were lysed using CelLyticTM MT Cell Lysis Reagent 
(Sigma, St. Louis, MO) with 1x Halt™ Protease and Phosphatase Inhibitor Cocktail, EDTA-free 
(ThermoFisher Scientific). Equal amounts of proteins were loaded and separated using a 12% 
SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) gel. The gel was then 
electrotransferred onto a nitrocellulose membrane and probed with rabbit anti-mouse Nav1.3 
(1:500, Alomone Labs), rabbit anti-mouse Nav1.6 (1:500; Alomone Labs), rabbit anti-mouse 
Nav1.7 (1:500, Alomone Labs), rabbit anti-mouse Nav1.8 (1:500, Alomone Labs), rabbit anti-
mouse Nav1.9 (1:500, Alomone Labs), rabbit anti-mouse Navβ2 (1:500, Alomone Labs), or 
mouse anti-β-actin (1:2000, Abcam) primary antibodies. Afterwards, the blots were probed using 
the appropriate horseradish peroxidase (HRP)-conjugated anti-rabbit/mouse secondary antibodies 
(1:5000; Bio-Rad Laboratories). Protein signals were visualized using enhanced 
chemiluminescence reagents (Bio-Rad) and quantified by densitometry using ImageJ software 
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(NIH).  All Nav protein signals were normalized to those of β-actin, and expressed as percent of 
control. 
  
2.6 Statistical Analysis. All data are reported as mean ± standard error of mean (SEM). A two-
way analysis of variance (ANOVA) followed by a Tukey’s post hoc test was used to analyze 
voltage-clamp (maximum peak current densities) and current-clamp (action potential frequency) 
data. For body weight and blood glucose measurements, we performed a repeated measures two-
way ANOVA followed by a Sidak’s post hoc analysis. A Student’s t-test or Mann-Whitney test 
was employed to analyze signal intensities between groups in western blotting, and to compare 
parameters in activation curves. In all cases, data with p values less than or equal to 0.05 were 
considered statistically significant. All statistical analyses were performed using InStat 3.0 or 
Prism 8 (both from GraphPad Software Inc., La Jolla, CA, USA). 
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CHAPTER 3 
RESULTS 
 
3.1 Short-term exposure of cultured DRG neurons to high glucose decreases neuronal 
excitability 
The passive membrane properties of all cells that I patch-clamped are reported in Table 3.1. 
There were no significant differences (p>0.05) found in membrane capacitance (Cm) expressed in 
picofarads (pF), and resting membrane potential (Vrest) expressed in millivolts (mV) between the 
control (CTL; 5 mM glucose) and high glucose (HG; 25 mM glucose) groups. 
  
As a measure of neuronal excitability, current-clamp recordings were utilized to study action 
potential (AP) firing frequency in cultured DRG neurons. APs were generated by the injection of 
100 pA depolarizing current for increments of 500 ms. APs were compared between CTL and 
HG groups using three perfusing solutions: no blockers, 1 µM tetrodotoxin (TTX), and 1 µM 
tetrodotoxin + 100 µM lidocaine (TTX + Lido). Exposure to HG for 10-14 days reduced evoked 
AP firing, with respect to CTL (Figure 3.1) and this reduction was statistically significant at a 
current injection of 500 pA (p<0.001) (Figure 3.1C). At 500 pA, the AP frequency (s-1) for the 
CTL and HG groups were 12.26 ± 2.58 and 3.88 ± 0.71, respectively. There were no significant 
differences (p>0.05) between the CTL and HG groups when TTX or TTX + Lido was added to 
the perfusing bath solution. The AP frequency for those groups are 6.69 ± 2.04 for CTL TTX, 
2.42 ± 0.19 for HG TTX, 2.00 ± 0.63 for CTL TTX + Lido, and 1.54 ± 0.24 for HG TTX + Lido. 
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Table 3.1. Passive membrane properties of DRG neurons in control and high glucose. There 
were no significant differences between the membrane capacitance (Cm; pF) and the resting 
membrane potential (Vrest; mV) between the control (CTL) and high glucose (HG) groups. 
Analyses were performed using Student’s t-tests. CTL: n=15, HG: n=18. 
 Cm (pF) Vrest (mV) 
CTL (n=15) 17.37 ± 1.17 -51.17 ± 1.31 
HG (n=18) 18.25 ± 1.02 -54.11 ± 1.66 
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Figure 3.1. Sensory neurons from the DRG fire fewer action potentials (APs) after short-term 
exposure (10-14 days) to high glucose. A. Representative current-clamp traces under control 
(CTL) and high glucose (HG) conditions, recorded with normal bathing solution, with 
tetrodotoxin (TTX), or with TTX + lidocaine (TTX + Lido). Recordings were generated using a 
current-clamp protocol (inset) from a holding potential of -60 mV. B-D. Line graphs demonstrate 
AP frequency (s-1) at different current step injections (pA) with no blockers (B), TTX (C), and 
TTX + Lido (D). E. Analysis at 500 pA indicates a significant reduction in AP frequency 
between CTL and HG conditions. Statistical analysis performed using a two-way ANOVA 
followed by a Tukey’s post hoc test. CTL n=27, HG n=32, CTL TTX n=16, HG TTX n=19, CTL 
TTX + LIDO n=5, HG TTX + LIDO n=13. ***indicates p<0.001. 
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3.2 Short-term exposure to high glucose decreases voltage-gated Na+ currents in DRG 
neurons 
To better understand the possible role of Nav channels in the decreased AP firing frequency in 
HG conditions, we studied voltage-gated Na+ currents in CTL and HG conditions. We used 
voltage-clamp electrophysiology, at a holding potential of -60 mV followed by a hyperpolarizing 
prepulse (-120 mV) to remove Nav inactivation and subsequent step voltages (-80 mV to +30 mV 
at 10 mV increments), to generate inward current including Nav currents. HG (10-14 days) 
caused a significant decrease in the peak current density with respect to control, in the three 
experimental conditions: CTL and HG (p<0.01), CTL TTX and HG TTX (p<0.001), and CTL 
TTX + Lido and HG TTX + Lido (p<0.05) (Figure 3.2). The maximum peak current densities 
(pA/pF) for each group are -165.27 ± 9.65 for CTL, -112.02 ± 11.96 for HG, -132.40 ± 10.22 for 
CTL TTX, -65.18 ± 10.97 for HG TTX, -83.31 ± 8.22 for CTL TTX + Lido, and -35.20 ± 8.28 
for HG TTX + Lido. 
  
To determine whether the effects of short-term exposure to high glucose were mediated by 
changes in the activation kinetics of Nav channels, we generated the activation curves shown in 
Figure 3.3. There were no significant differences in the membrane potential for half-maximal 
activation (Vhalf) between CTL (-28.48 ± 1.74 mV) and HG (-31.77 ± 12.68 mV) groups. 
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Figure 3.2. Sensory neurons from the DRG generate less inward currents in HG. A. 
Representative voltage-clamp traces in CTL (top) and HG (middle) conditions generated by the 
protocol displayed at the bottom. The orange arrow points at a representative example of inward 
currents. B-D. Line graphs display the mean ± SEM of the peak current densities (pA/pF) plotted 
against voltage step (mV) with no blockers (B), TTX (C) and TTX + Lidocaine (D). E. The 
maximum peak current densities (pA/pF) show significant reductions between CTL and HG, 
CTL TTX and HG TTX, and CTL TTX + Lido and HG TTX + Lido. Note, maximum peak 
current densities were reported as positive values for easier visualization in E. Statistical analysis 
was performed using two-way ANOVA followed by Tukey’s post hoc test. CTL n=15, HG 
n=18, CTL TTX n=14, HG TTX n=18, CTL TTX + Lido n=14, HG TTX + Lido n=16. 
*indicates p<0.05, **indicates p<0.01, ***indicates p<0.001. 
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Figure 3.3. Activation curves for voltage-gated inward currents in DRG neurons. There was no 
significant difference in activation parameters between CTL and HG. Current-voltage curves 
from Figure 3.2B were converted to conductance-voltage relationships and fitted into a 
Boltzmann equation as described in Materials and Methods. Statistical analysis performed by 
Student’s t-test. CTL n=15, HG n=18. 
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3.3 Short-term diabetes decreases the expression levels of TTX-S Nav subunits 
To determine whether the observed effects of high glucose on Nav currents in vitro were 
reflected by changes in the expression levels of Nav subunits in the DRG in vivo, we employed a 
mouse model of diabetes. In the present study, Nav expression levels were analyzed at one 
month, as a short-term time point, and at three months, as a long-term time point, after STZ-
induction of diabetes. 
  
The body weights and blood glucose levels of the mice included in the one-month group are 
reported in Figure 3.4A-B. Figure 3.4A displays the mouse body weights, which were 23.31 ± 
0.53 g for the initial weight of CTL mice, 20.50 ± 0.32 g for the initial weight of STZ mice, 24.87 
± 0.49 g for the final weight of CTL mice, and 21.04 ± 0.46 g for the final weight of STZ mice. 
The initial and final body weights of the CTL group were statistically different from one another 
(p<0.01). We also found significant differences between the initial body weights of the CTL vs 
STZ (p<0.001) and between the final body weights of CTL vs STZ (p<0.001) groups. Figure 
3.4B displays the blood glucose levels of the mice included in the one-month group, which were 
9.14 ± 0.42 mM for the initial of CTL, 9.87 ± 0.33 mM for the initial of STZ, 8.46 ± 0.32 mM for 
the final of CTL, and 31.73 ± 0.89 mM for the final of the STZ group. The final blood glucose of 
the STZ group is significantly higher than those of CTL (p<0.001) and the initial levels of the 
STZ group (p<0.001), confirmed diabetic conditions in these animals. 
  
At one month after STZ-induced diabetes, there were significant downregulations in the 
expression levels of different Nav subunits. Reported as percentages of control (%), the Nav 
protein expression levels were 74.05 ± 2.30 for Nav1.3, 70.93 ± 5.32 for Nav1.6, 77.23 ± 1.87 for 
Nav1.7, 93.35 ± 7.51 for Nav1.8, 89.06 ± 8.33 for Nav1.9, and 67.91 ± 7.02 for Navβ2 (Figure 
3.4C-D). There were significant reductions for Nav1.3, Nav1.6, Nav1.7 and Navβ2. Interestingly, 
all three Nav α-subunit isoforms are TTX-S. 
  
Next, we used a group of animals that had been STZ-induced diabetic for 3 months. Body 
weights and blood glucose levels are illustrated in Figure 3.5A-B. The initial body weights were 
20.16 ± 0.64 g for CTL and 20.89 ± 0.56 g for STZ and the final body weights were 30.25 ± 0.80 
g for CTL and 25.44 ± 1.33 g for STZ. The final body weights for both groups were significantly 
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different from their corresponding initial measurements (p<0.001 for CTL and p<0.01 for STZ) 
and the final body weight of the STZ group is significantly lower (p<0.001) than those of CTL. 
The initial blood glucose levels of the three-month group were 11.55 ± 0.64 mM for CTL and 
12.80 ± 0.36 mM for STZ and the final blood glucose levels were 8.78 ± 0.28 mM for CTL and 
31.60 ± 1.16 mM for STZ. The final blood glucose measurements of both groups were 
significantly different from their corresponding initial values (p<0.01 for CTL and p<0.001 for 
STZ). In addition, the final blood glucose level of the STZ group was significantly higher 
(p<0.001) from those of the CTL group, which again confirms diabetic states. 
  
Biochemical analysis of lumbar DRG samples collected from animals made diabetic by STZ for 
three months show a striking difference from the Nav subunit expression profile observed at one-
month diabetes (Figure 3.5D). At three months, we found a significant increase in the expression 
levels of the TTX-S Nav1.7. Expressed as a percentage of CTL, the protein expression level of 
Nav1.7 became 180.97 ± 6.35% three months after the induction of diabetes, while there were no 
significant changes in the rest of the Nav subunits. For the rest of the subunits, their protein 
expression levels in percent (%) were as follows: 102.76 ± 9.37 for Nav1.3, 117.35 ± 9.16 for 
Nav1.6, 191.95 ± 19.13 for Nav1.8 (p=0.057), 181.99 ± 34.84 for Nav1.9 (p=0.200), and 123.36 
± 17.35 for Navβ2. 
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Figure 3.4. Initial and final body weights (A) and blood glucose levels (B) of the animals used 
for the one-month STZ-diabetic group. Significant differences were found in the initial and the 
final body weights between CTL and STZ groups, and between the initial and final values in the 
CTL group. In addition, the final blood glucose level of the STZ group was statistically higher 
than the initial of the STZ and the final of the CTL group. C. Representative immunoblots 
showing detection levels of various Nav channel subunits from intact DRG tissues collected from 
CTL and STZ-diabetic mice at one month after induction of diabetes. D. Bar graphs summarize 
the quantification of protein levels normalized to β-actin and expressed as percentages of control. 
There were statistically significant reductions in the expression levels of Nav1.3, Nav1.6, Nav1.7 
and Navβ2. All three α-subunits are TTX-S. Statistical analyses were done by two-way repeated 
measures ANOVAs followed by Sidak’s post hoc tests for A and B (CTL n=31, STZ n=42) and 
Student’s t-tests for D (n=5 per group). *, indicates p<0.05;  **, indicates p<0.01; ***, indicates 
p<0.001. 
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Figure 3.5. Initial and final body weights (A) and blood glucose levels (B) of CTL and STZ mice 
of the three-month STZ-diabetic group. The final weights of the CTL and STZ groups are 
statistically different from their own initial values and the STZ final weight is also statistically 
different from the CTL final weight. The final blood glucose levels of the CTL and STZ groups 
were statistically significant from their corresponding initial measurements and the STZ final 
blood glucose level was statistically higher than the CTL and STZ initial values. C. 
Representative immunoblots showing detection levels of various Nav channel subunits from 
intact DRG tissues collected from CTL and STZ-diabetic mice at three months after induction of 
STZ-diabetes. D. Bar graphs summarize the quantification of protein levels normalized to β-actin, 
and expressed as percentages of control. There was a significant increase in the expression level 
of the TTX-S Nav1.7 subunit. Statistical analyses were performed by two-way repeated measures 
ANOVA followed by Sidak’s post hoc tests for A and B (CTL n=16, STZ n=9), and non-
parametric Mann-Whitney test for D (n=3 per group for Nav1.3, and n=4 per group for the rest of 
the subunits). *, indicates p<0.05; **, indicates p<0.01;  ***, indicates p<0.001. 
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CHAPTER 4 
DISCUSSION AND CONCLUSION 
 
4.1 Effect of High Glucose and Short-Term Diabetes on DRG Neurons 
Diabetic peripheral neuropathy (DPN) manifests through many sensory abnormalities that at 
advanced stages of the disease are accompanied by structural abnormalities in affected sensory 
nerves. Although DPN has been traditionally considered as resulting from long-standing diabetes, 
many studies demonstrate the prevalence of DPN in disorders with a very different and shorter 
time course, such as in prediabetic patients (Stino and Smith, 2017; Wilson, 2017) or in children 
diagnosed with Type 1 diabetes (Louraki et al., 2012). In addition, further challenging the 
traditionally-accepted view, research on DRG neurons in vitro show that high glucose can have 
detrimental effects on sensory neurons independent from glia- or blood vessels-mediated effects, 
and that sensory neuron abnormalities can develop in a matter of 1-2 weeks (Russell et al., 1999; 
Lam et al., 2018). 
  
Therefore, a better understanding of the molecular, biochemical and functional mechanisms that 
contribute to the pathology of DPN is required. In this study, we demonstrate that short-term 
exposure (10-14 days) of DRG neurons to high glucose alters the function of Nav channels. 
Contrasting with the known effect of hyperglycemia on DRG neurons, which leads to increased 
sensory responses (e.g. to capsaicin) (Pabbidi et al., 2008; Lam et al., 2018), our study showed 
that 1-2 weeks of high glucose treatment caused a decrease in sensory neuron responses, such as 
reduction in the generation of action potentials. Consistent with this finding, we observed 
reduced inward currents, without alteration in activation kinetics.  
 
It is important to point out that in the presence of TTX alone, high glucose was still effective in 
reducing the inward currents compared to CTL (i.e. CTL TTX vs HG TTX).  This reduction 
could be attributed to failure in total block of TTX-S currents in CTL and/or HG conditions, or to 
another type of inward current affected by HG. The latter is supported by preliminary data 
(unpublished observations) from our own laboratory indicating that T-type Ca2+ currents are 
significantly reduced by the high glucose treatment. Further research is required to understand the 
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combined effect of high glucose and short-term diabetes on Nav and T-type Ca2+ currents, and 
how this impacts cell excitability.  
 
Our western blotting experiments support the idea that short-term diabetes and high glucose 
impact TTX-S Nav channels. In the DRG of animals one month after the induction of diabetes, 
we observed a reduction in the expression levels of the TTX-S subunits of Nav channels. The 
observed decrease in inward currents contrast with previous reports on the function of Nav 
channels in the DRG of diabetic animal models (Hirade et al., 1999; Hong et al., 2004; Kharatmal 
et al., 2015). This opposite effect could be attributed at least in part to the age of our experimental 
animals, which were neonates for our in vitro model. A study by Kharatmal and colleagues 
(2015) demonstrated increased TTX-R current densities in DRG neurons exposed to high glucose 
conditions of 30 mM for 24 hours. This study was performed on 3-4 month old rats, while our 
experiments utilized DRG neurons from mice pups 0-4 days postnatally. Despite the 
contradictory findings, both studies support the notion that short-term exposure to high glucose 
exerts functional effects on Nav channels independent of the structural and vascular changes 
associated with long-term diabetes (Bellini et al., 2017). In addition, studies from animal models 
of STZ-diabetes reported increases in Nav currents (Hirade et al., 1999; Hong et al., 2004). These 
studies were performed on STZ-induced diabetic rats, which ranged from ages of 4 weeks to 8 
months old, while our studies were performed on neonatal mice for in vitro experiments. 
Moreover, their electrophysiological recordings were performed 2-7 hours after cell preparation, 
while our primary DRG cultures were allowed 5 days to recover before we exposed them to high 
glucose conditions. Considering that the trauma of axotomy during neuronal isolation is known to 
induce oxidative stress, which can trigger apoptotic signalling (Sayir et al., 2013), the contrasting 
findings could be potentially based on the health of the culture neurons. In a recent publication 
from our team (Lam et al., 2018), we addressed this point by demonstrating that cultured DRG 
neurons exposed to high glucose were under oxidative stress, but not in an apoptotic state.       
  
Thus, our study revealed that short-term exposure (10-14 days) to high glucose decreases DRG 
neuron excitability and we provided evidence for possible early functional changes that occur in 
DPN, potentially when patients are still asymptomatic. Considering that variability in the species 
and experimental designs between our study and previously reports may be contributing to the 
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differences in findings, it will be relevant to investigate electrophysiological properties of DRG 
neurons from our adult STZ-diabetic animals. 
  
To validate our in vitro findings, we employed a diabetic mouse model. We observed some 
unpredicted effects on body weight and blood glucose levels that are worth further considering.  
First, we observed a significant difference between the initial body weights of the CTL and STZ 
mice in our one-month group. We can only attribute that difference to chance during animal 
selection for the experimental groups, wherein the STZ group were a batch of smaller animals 
compared to the CTL group.  Second, in both the one- and three-month groups, the final body 
weight of the STZ group was significantly lower than those of CTL mice, which is consistent 
with previous reports of the link between STZ-induced diabetes and weight loss due to factors 
such as an increase in urine output (Graham et al., 2011), which possibly contributed to the 
decrease in the final weight of the STZ group. Third, we observed that the initial blood glucose 
levels of both groups were higher than expected for young control mice (10.6-14.9 mM). This 
effect could be explained by the effect of the anesthetic isoflurane, which is known to increase 
blood glucose levels (Windeløv, Pedersen, & Holst, 2016). Accordingly, once isoflurane was 
avoided before euthanasia, the final blood glucose levels of CTL animals were within the normal 
range (i.e. 10.5 mM or lower).  
  
4.2 Changes in Expression Levels of Nav Subunits during Diabetes 
 Our study of the expression levels of Nav channels in intact DRG tissues, showed significant 
decreases in the expression levels of various TTX-S Nav subunits (Nav1.3, Nav1.6 and Nav1.7) 
one month after STZ-induced diabetes. It is interesting to note that only the TTX-S subunits 
showed significant decreases in expression levels, while the TTX-R subunits (Nav1.8 and 
Nav1.9) were unaffected by short-term diabetes. A potential explanation for this selective 
downregulation of TTX-S subunits would be the significant reduction in the Navβ2 subunit, 
which has been linked to reduced expression levels of TTX-S Nav subunits (Lopez-Santiago et 
al., 2006) as will be discussed in this section. Here, we considered the changes in expression 
levels of the different Nav subunits and possible implications this may entail on DRG neuron 
excitability. 
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First, Nav1.3 has been reported to be expressed at practically undetectable levels in adult DRG 
neurons, but is significantly upregulated after peripheral axotomy or nerve damage (Waxman et 
al., 1994; Black et al., 1999). Peripheral nerve injuries such as chronic constriction injury, 
neuroma formation after peripheral nerve transection, and experimental painful diabetic 
neuropathy cause upregulation of Nav1.3 expression levels (Parnham et al., 2005; Wang et al., 
2011). Nav1.3 mediates a TTX-S current that rapidly recovers from inactivation, which is able to 
support high frequency firing and thus contribute to injury-induced hyperexcitability (Benarroch, 
2007). In the present study, we demonstrated a robust expression of Nav1.3 in the DRG of both 
control and STZ-diabetic mice. We also showed a decrease in Nav1.3 expression one month 
following STZ-induced diabetes, which could contribute to the reduction in AP firing frequency 
we have observed in the DRG neurons in vitro. 
  
Nav1.6 is reportedly the predominant Nav isoform expressed in the nodes of Ranvier of 
myelinated sensory axons, as well as along axons of unmyelinated C-fibres (Parnham et al., 
2005; Wittmack, 2005; Wang et al., 2011). Hong and Wiley (2004) demonstrated a 
downregulation in Nav1.6 signal intensities in nodes in diabetic animals, but at the same time an 
increase in serine/threonine and tyrosine phosphorylation of Nav1.6 (Hong et al., 2004). It has 
also been reported that p38 phosphorylation of Nav1.6 leads to a significant reduction in Nav1.6 
peak current amplitude without any effects on gating properties (Wittmack, 2005). Consequently, 
p38 phosphorylation of Nav1.6 provides a potential mechanism for slowing nerve conduction in 
DSN (Tomlinson and Gardiner, 2008). The kinase p38 belongs to the MAPK (mitogen-activated 
protein kinases) family, which are activated in response to stress. Moreover, the p38 pathway is 
activated in diabetes and is downstream of the RAGE signalling cascade (Yeh et al., 2001). As 
mentioned, we recently demonstrated a RAGE-dependent potentiation of capsaicin-evoked 
currents in DRG neurons exposed to short-term high glucose (Lam et al., 2018). Thus, the RAGE 
signalling pathway provides a link between Nav subunits and TRPV1 channels that is worth 
investigating in the future. 
  
Nav1.7 is predominantly expressed in small DRG neurons, and it has been proposed that Nav1.7 
may be physiologically coupled to Nav1.8 (Parnham et al., 2005; Wang et al., 2011). Nav1.7 is 
considered a threshold channel because it amplifies subthreshold stimuli in order to activate 
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Nav1.8, which is responsible for mediating the majority of Nav currents during the upstroke of an 
action potential (De Lera Ruiz and Kraus, 2015). Nav1.7 has been implicated in many studies of 
experimental DPN. Hoeijmakers and colleagues (2014) even proposed that the pathologies of 
DPN and diabetes occur in parallel with one another. They suggested that both result from 
mutations in the Nav1.7 gene, which render neurons and pancreatic β cells susceptible to the 
development of DPN and diabetes, respectively (Hoeijmakers et al., 2014). Moreover, it is well 
known that mutations in the Nav1.7 gene give rise to a number of pain disorders, including 
congenital insensitivity to pain, paroxysmal extreme pain disorder, and primary erythromelalgia. 
The congenital insensitivity to pain results from loss-of-function mutations, while paroxysmal 
extreme pain disorder and primary erythromelalgia are due to gain-of-function mutations in the 
Nav1.7 gene (Wang et al., 2011; De Lera Ruiz and Kraus, 2015).  Taken together, the central role 
of Nav1.7 in pain perception suggests a pivotal role in DPN. We observed a decrease in Nav1.7 
expression levels one month after STZ-induced diabetes and considering the role of Nav1.7 in 
other pain disorders, this reduction may potentially contribute to the sensory abnormalities 
(numbness, weakness and paresthesia) observed in DPN. However, at three months after STZ-
induced diabetes, we observed a significant upregulation in Nav1.7, which is consistent with the 
previous reports on DPN (Hong et al., 2004; Hong and Wiley, 2006). 
  
Nav1.8, along with Nav1.9, are selectively expressed in small DRG neurons (Parnham et al., 
2005; Wang et al., 2011). As mentioned above, it has been reported that Nav1.8 carries most of 
the inward current during the initial spike of the action potential (Yang et al., 2016). Furthermore, 
under high glucose conditions, there is an increase in the formation of the highly reactive 
glycolytic metabolite methylglyoxal, which has been proposed to depolarize sensory neurons by 
inducing posttranslational modifications of Nav1.8 (Bierhaus et al., 2012; De Lera Ruiz and 
Kraus, 2015). The second TTX-R Nav channel in DRG neurons is Nav1.9, which generates 
persistent current activated at low voltage thresholds, and thus is believed to contribute to the 
resting membrane potential (Parnham et al., 2005). One month after induction of diabetes, we did 
not observe any differences in expression levels of Nav1.8 and Nav1.9 under early diabetic 
conditions. However, at three months, we observed a trend suggesting an increase in expression 
levels of these TTX-R subunits. Nav1.8 and Nav1.9 have been implicated in many models of 
neuropathic pain since they play key roles in the excitability of neurons (Lauria et al., 2014; 
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Tibbs et al., 2016). Again, similar to Nav1.7, these two Nav isoforms may potentially be 
contributing to increased pain responses occurring in DSN. 
  
The Navβ2 subunit is covalently linked by a disulfide bond to the α-subunit of Nav channels 
(Schmidt and Catterall, 1986). Typically, there is a stable free intracellular pool of newly 
synthesized α-subunit, and disulfide linkage to the Navβ2 subunit is required for its plasma 
membrane mobilization (Schmidt and Catterall, 1986). β2—/— mice display reductions in Nav cell 
surface expression (Chen et al., 2002). DRG neurons from β2—/— mice show reductions in TTX-
S Nav currents compared to those from β2+/+ mice and also show decreased transcripts and 
protein levels of Nav1.7 (Lopez-Santiago et al., 2006). Lopez-Santiago and colleagues (2006) 
suggested that the Navβ2 subunit regulates the cell surface expression of TTX-S Nav channels, 
but not TTX-R Nav channels. Moreover, the upregulation of the Navβ2 subunit in peripheral 
nerve injury may contribute to hyperexcitability and ectopic firing by recruiting Nav channels to 
the cell surface (Pertin, 2005). Given this evidence, it is plausible that the decrease in Navβ2 in 
the present study is responsible for the reductions in the expression levels of the TTX-S subunits 
(Nav1.3, Nav1.6 and Nav1.7). If this is so, targeting Navβ2 during early DPN could reverse the 
dysregulation of the involved Nav channels. 
  
Taken together, our study shows changes in the expression levels of Nav subunits that correlate 
with electrophysiological abnormalities in action potential generation and Na+ currents in DRG 
neurons exposed to high glucose conditions. Although we did not correlate these effects of high 
glucose with pain perception in STZ-diabetic mice, we propose that our finding may contribute to 
the paradoxical sensation of numbness and loss of perception that can take in place in short-term 
diabetes (Christianson et al., 2003). Furthermore, our study also revealed that diabetes could 
affect the expression levels of Nav subunits in different ways depending on the stage of the 
disease. While we observed a reduction in TTX-S Nav subunit expression at one month of 
diabetes, this effect was switched to a significant increase in the expression of Nav1.7 at three-
month time point. We did not detect significant changes in the expression levels of Nav1.8 and 
Nav1.9, but rather a seemingly increasing trend, considering that these two Nav isoforms have 
been implicated in pain abnormalities (Priest et al., 2005; Rush et al., 2006; Bierhaus et al., 2012; 
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Zhang et al., 2013), future research should be designed to look at the potential change in the 
expression profile and role of Nav1.8 and Nav1.9 in later stages of DSN. 
  
4.3 Future Directions and Limitations 
As mentioned above, a limitation of this study is that we employed neonatal DRG neurons for 
our in vitro studies, while using young adult DRG tissue samples for our western blotting 
experiments. Our team did try to run western blotting analysis on our cultured DRG samples, but 
due to low protein concentrations of the Nav subunits in our model, we were unable to detect 
reliable signals. Instead, we decided to utilize an STZ-diabetic mouse model to validate our in 
vitro findings, and test the relevance of our in vitro results in DRG neurons exposed to the host of 
metabolic insults that occur in diabetes. Moreover, for future studies, it would be interesting to 
see the functional differences between Nav channels from STZ-induced diabetic and control 
mice. Secondly, since we observed a decreasing trend for inward currents that are not from Nav 
channels, it would be worth investigating the roles of T-type calcium channels during the onset of 
DPN. Tibbs and colleagues (2016) discussed the involvement of voltage-gated Calcium (Ca2+) 
channels in neuropathic pain. Considering that T-type Ca2+ channels Cav3.2 and Cav3.3 are 
expressed in DRG neurons and may play a role in the pathogenesis of DPN, they may be 
potential targets to treat DPN. 
 
Finally, our study concentrated on cellular and molecular effects of short-term hyperglycemia in 
DRG neurons, but to fully understand the relevance of our findings for DPN behavioural studies 
will be required. Such an approach was beyond the scope of our project, but future research 
designed to better understand the correlation between changes in Nav channel function and 
expression with the development of the known DPN symptoms, such as hyperalgesia, allodynia, 
numbness and loss of pain perception, will shed new light on not only the etiology of this 
pathology, but also on new therapeutic targets. 
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